Evelyn Warner, Author at Labiotech.eu

About

Ex-Editor. Recovering organic chemist. Chagrined member of the Brooklyn-Berlin exchange program. Proud parent of a majestic domestic long hair.

Articles by Evelyn Warner

News and Trends 26 Sep 2016

Terrible Turing hasn’t given up on Toxoplasmosis (or its Karma)

The biopharmaceutical company’s Swiss division just published computational studies aiming to improve Daraprim, after its former CEO, Martin Shkreli, attempted to justify the scandalous 5000% price hike as a boost for its R&D. A little over a year ago, Martin Shkreli, founder and then-CEO of Turing Pharmaceuticals, hiked the price of a common medication for toxoplasmosis by […]

September 26, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 23 Sep 2016

SELLAS wants to sell us an Immunotherapy for Mesothelioma

After Cyprus, we mosey back to the mainland to visit the country gave the world the cuckoo clock. That’s right, we’re Schweiz-bound. In Switzerland, we’ll meet an immuno-oncology biotech, SELLAS Life Sciences. City: Zug (Zurich-area), Switzerland Founded: 2012 Employees: 11 – 50 Financial Data: None available…what a secretive cohort. Mission: SELLAS Life Sciences is a development-stage biopharmaceutical company focused on […]

September 23, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 23 Sep 2016

The Munich Biotech Mafia are at it again, raising €40M for an I/O Startup

A new immuno-oncology startup has taken off with a booming round of VC fundraising. Details on its programs are sparse, but the company’s leadership is a veritable who’s who in German biotech, much like the PayPal Mafia. Immuno-oncology is surely an exciting field, but high-profile leadership is a huge bonus when it comes to attracting […]

September 23, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 21 Sep 2016

German Biotech allies with Genentech in battle for Cancer Vaccine

BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […]

September 21, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 20 Sep 2016

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Novartis is poised to kick off the next generation of multiple sclerosis treatments after siponimod performs well in Phase III. The company’s primary competitor had been Biogen, but its drug’s failure in Phase II leaves siponimod the last man standing. Novartis reports that its multiple sclerosis (MS) drug, siponimod, has reached its primary endpoint in Phase III […]

September 20, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 19 Sep 2016

Novozymes moves on Microbes in recent Acquisition

The world’s leading producer of enzymes is making moves in the microbial world. Novozymes just acquired Organobalance, a German biotech specializing in microbes. Novozymes is a pillar of the Danish biotech scene and the world’s leading enzyme manufacturer. In 2000, it spun out of Novo Nordisk under the supervision of the World’s Best CEO, and […]

September 19, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 19 Sep 2016

Abingworth launches UK Immuno-Oncology Startup with Seed Funding

Just when we thought it couldn’t become any more intense, the field of immuno-oncology is heating up. VC giant Abingworth has seeded a new UK startup, GammaDelta Therapeutics, to bring its T cell therapy to the clinic. Abingworth, a huge British VC firm, has thrown its weight behind a new London-based immuno-oncology startup, GammaDelta Therapeutics. […]

September 19, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 17 Sep 2016

This Slovenian Artist creates gorgeous Soundscapes from Underwater Worlds

The annual Ars Electronica festival for digital art took Linz, Austria, last weekend and featured Slovenian bioartist Robertina Šebjanič in the Underworld bunker of its POSTCITY venue. She builds beautiful underwater gardens and translates them into sound, and one of them, Aurelia 1+Hz, won an Honorary Mention at the festival! Based in Ljubljana, Robertina explores living […]

September 17, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 16 Sep 2016

This new Biotech is bringing the industry to Cyprus

To celebrate the end of summer, we make our getaway from Vienna to a Mediterranean island for one last hurrah. This week, we are visiting algae-focused Perpetual Biotechnologies, our Biotech of the Week. City: Nicosia Founded: 2015 Employees: 6 Financial Data: €1.2M Total Raised (as of 01/2016) CEO: Michalis Kouloumis (pictured), Constantinos Avgoustou Mission: Perpetual Biotechnologies focuses on developing renewable […]

September 16, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 16 Sep 2016

Children of Men: Artificial Embryos could let Anyone be a Parent

A team at the University of Bath has successfully raised not just one mouse, but three entire generations of mice from cells incapable of growing into an embryo. These results have wild implications for infertile women, impotent men, gay couples, and women who simply wish to avoid the burden of pregnancy. The human race is […]

September 16, 2016 - 2 minutesmins - By Evelyn Warner

multiple sclerosis by decade3d anatomy online FI

News and Trends 15 Sep 2016

Roche’s New Antibody is besting the best MS Drug

Roche is poised to blow away the competition for the new multiple sclerosis drug with its leading candidate, Ocrevus (ocrelizumab). Phase III data shows it outperforming Merck’s Rebif, the standard therapy for MS. Competition for a new MS drug has been stiff, but new promising data from the Phase III trial of Ocrevus (ocrelizumab) suggests […]

September 15, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 15 Sep 2016

Too good to be true: Sanofi Pasteur’s Dengue vaccine raises Serious Concerns

Before Sanofi Pasteur distributed its dengue vaccine, Dengvaxia, there were some concerns that it would actually make people sicker. A new study from top universities has found this to be the case in some areas. Researchers from Johns Hopkins Bloomberg School of Public Health, Imperial College London and the University of Florida have confirmed critics’ […]

September 15, 2016 - 3 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us